Securities law violation

Search documents
KBR, Inc. (KBR) Shares Sharply Declined Amid TRANSCOM Contract Termination– Hagens Berman
GlobeNewswire News Room· 2025-07-01 20:19
SAN FRANCISCO, July 01, 2025 (GLOBE NEWSWIRE) -- On June 20, 2025 investors in KBR, Inc. (NYSE: KBR) saw the price of their shares decline over 7% after the company announced that the Department of Defense U.S. Transportation Command (“TRANSCOM”) cancelled its global household goods contract (“contract”) awarded to HomeSafe Alliance LLC, a KBR led joint venture. This announcement has prompted national shareholders rights firm Hagens Berman to open an investigation into whether KBR may have violated the secu ...
Compass Group Diversified Holdings, LLC Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before July 8, 2025 to Discuss Your Rights – CODI
GlobeNewswire News Room· 2025-06-26 20:40
Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Compass Group Diversified Holdings, LLC (NYSE: CODI) regarding a class action lawsuit due to alleged failures in financial reporting and internal controls [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Compass failed to disclose effective internal controls over financial reporting and critical information regarding its subsidiary, Lugano Holding, Inc. This included undisclosed financing arrangements and irregularities in sales, cost of sales, inventory, and accounts receivable [3]. - The truth about these issues emerged on May 7, 2025, when Compass announced that its financial statements for fiscal 2024 could no longer be relied upon due to an internal investigation into Lugano [3]. - Following this announcement, Compass's stock price plummeted from $17.25 per share on May 7, 2025, to $6.55 per share on May 8, 2025 [3]. Next Steps for Shareholders - Shareholders who purchased shares of CODI during the class period (February 24, 2022, to May 7, 2025) are encouraged to register for the class action by July 8, 2025 [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the case [4]. Law Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements or omissions that led to stock inflation [5].
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Guaranty Bancshares, Inc.
Prnewswire· 2025-06-25 22:36
Core Viewpoint - Rowley Law PLLC is investigating potential securities law violations related to the proposed acquisition of Guaranty Bancshares, Inc. by Glacier Bancorp, Inc. [1] Group 1: Acquisition Details - The proposed acquisition involves stockholders of Guaranty Bancshares receiving 1.00 share of Glacier Bancorp common stock for each share of Guaranty Bancshares stock held [1] - The transaction is valued at approximately $476.2 million and is expected to close in the fourth quarter of 2025 [1]
Hims & Hers Health, Inc. (HIMS) Shares Crash After Novo Nordisk Cancels Partnership Over "Deceptive" Marketing of Wegovy, Faces Investor Scrutiny- Hagens Berman
Prnewswire· 2025-06-25 18:08
Core Viewpoint - Hims & Hers Health, Inc. experienced a significant share price drop of over 30% following the termination of its collaboration with Novo Nordisk due to concerns regarding sales practices and marketing of the weight loss drug Wegovy® [1][4]. Company Summary - Hims & Hers Health, Inc. had previously partnered with Novo Nordisk to provide access to Wegovy®, which is FDA-approved for obesity treatment, through its platform [3]. - The partnership was short-lived, as Novo Nordisk cited "illegal mass compounding and deceptive marketing" as reasons for the termination [4]. - Hims & Hers had previously assured investors of its regulatory compliance, claiming it was not bypassing the regulatory process [2]. Investigation Summary - Hagens Berman, a national shareholders rights firm, has initiated an investigation into potential violations of securities laws by Hims & Hers, urging affected investors to report their losses [2]. - The investigation will focus on whether Hims & Hers misled investors regarding the marketing of potentially unsafe versions of Wegovy® [4].
CTO Realty Growth, Inc. (CTO) Shares Decline Amid Wolfpack Report– Hagens Berman
GlobeNewswire News Room· 2025-06-25 17:26
Core Viewpoint - The share price of CTO Realty Growth, Inc. significantly declined following allegations from Wolfpack Research regarding misleading statements about dividend sustainability and questionable financial practices [1]. Group 1: Allegations and Investigations - Hagens Berman, a national shareholders rights firm, has initiated an investigation into CTO Realty Growth, Inc. to determine if the company violated securities laws and is urging affected investors to report their losses [2]. - The investigation focuses on CTO's claims of adhering to accounting rules and the use of non-GAAP accounting metrics, particularly concerning the quality of its real estate portfolio and reported asset values [3][5]. Group 2: Financial Distress and Management Practices - Wolfpack Research's report indicates that CTO's management has misrepresented the quality of its properties, revealing that some are in severe financial distress and that the company relies on dilution to cover a $38 million dividend shortfall [4]. - The report criticizes CTO's definition of Adjusted Funds From Operation (AFFO), claiming it excludes recurring capital expenditures, which is not consistent with industry peers, and suggests that management's compensation is inflated based on this metric [5]. Group 3: Whistleblower Information - Whistleblowers with non-public information about CTO Realty Growth are encouraged to assist in the investigation, with potential rewards under the SEC Whistleblower program for original information leading to successful recovery [6].
ZEO Investors Have Opportunity to Join Zeo Energy Corp. Fraud Investigation with the Schall Law Firm
Prnewswire· 2025-06-24 14:59
LOS ANGELES, June 24, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zeo Energy Corp. ("Zeo" or "the Company") (NASDAQ: ZEO) for violations of the securities laws. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the app ...
NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm
Prnewswire· 2025-06-24 07:42
Group 1 - The Schall Law Firm is investigating claims on behalf of investors of NeuroPace, Inc. for potential violations of securities laws [1] - The investigation centers on whether NeuroPace made false or misleading statements or failed to disclose important information to investors [2] - NeuroPace's press release on May 27, 2025, revealed that the NAUTILUS study did not achieve statistical significance for its primary effectiveness endpoint, leading to a nearly 28.4% drop in shares on the same day [2]
PTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
Prnewswire· 2025-06-24 07:42
Core Viewpoint - The Schall Law Firm is investigating PTC Therapeutics, Inc. for potential violations of securities laws related to misleading statements and failure to disclose important information to investors [1][2]. Group 1: Investigation Details - The investigation centers on whether PTC issued false or misleading statements regarding the results of the Phase 2 PIVOT-HD study of PTC518 (votoplam) in Huntington's disease patients [2]. - PTC announced that the study met its primary endpoint of reducing blood Huntingtin (HTT) protein levels with a significant p-value of less than 0.0001 at Week 12, along with favorable safety and tolerability [2]. - Analysts suggest that a Phase 3 study is necessary to confirm if the treatment effectively slows the progression of Huntington's disease, leading to a significant drop in PTC's share price by over 18.6% on the announcement day [2].
Hims & Hers Health, Inc. (HIMS) Shares Crash After Novo Nordisk Cancels Partnership Over “Deceptive” Marketing of Wegovy, Faces Investor Scrutiny – Hagens Berman
GlobeNewswire News Room· 2025-06-23 21:49
SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- On June 23, 2025 investors in Hims & Hers Health, Inc. (NYSE: HIMS) saw the price of their shares crash over 30% after Novo Nordisk announced that it terminated its collaboration with the telehealth company due to concerns about Hims & Hers’ sales and “deceptive” marketing of the weight loss drug Wegovy®. This news has prompted national shareholders rights firm Hagens Berman to open an investigation into possible violations of the securities laws. The firm ur ...
3D Systems Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before August 12, 2025 to Discuss Your Rights – DDD
GlobeNewswire News Room· 2025-06-23 20:00
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of 3D Systems Corporation (NYSE: DDD). Shareholders who purchased shares of DDD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/3d-systems-corporation-loss-submission-form/?id=153688&from=3 CLASS PERIOD: Aug ...